Quanterix Corp. announced its partnership with the Alzheimer’s Drug Discovery Foundation to accelerate the development of a multi-analyte plasma test for the early detection of Alzheimer’s disease.

Through this partnership, the Alzheimer’s Drug Discovery Foundation (ADDF) will fund a series of clinical trials to validate the test in collaboration with Amsterdam University Medical Centers.

“We are at a historic moment with plasma-based biomarkers for the detection of Alzheimer’s disease approaching clinical implementation,” Charlotte E. Teunissendoctorate, a professor at UMC Amsterdam who will lead the trials for the ADDF, said in a statement released by the foundation. “This partnership and funding with the ADDF will help accelerate rapid progress in this area just in time for the arrival of new therapies. We will seek to validate the Simoa multi-analyte test for use in both memory care and primary care, in people with concerns about their cognition.

The research will be coordinated by Quanterix’s Simoa Accelerator Services Lab, which supports research for more than 400 companies and accelerates drug approval times through biomarker detection at the lowest possible levels.

“We have long believed that the path to approved treatments for Alzheimer’s disease begins with a better way to diagnose patients and monitor their response to treatment,” Howard fill it upMD, ADDF co-founder and chief medical officer, said in the statement. “Through the Diagnostics Accelerator, the ADDF is accelerating the development of new biomarkers for the early detection of Alzheimer’s disease and related dementias, which are critical to advancing research, allowing us to enroll the right patients. in clinical trials and monitor their progress.